A 21-year-old woman with chronic myelogenous leukemia (CML) relapsed into lymphoblastic crisis with new chromosomal translocations, 4 months following mismatched unrelated allogeneic bone marrow transplantation (BMT). Adoptive cell-mediated immunotherapy with mismatched unrelated donor lymphocytes followed by 3 days of in vivo interleukin-2 (IL-2) resulted in complete remission including disappearance of the Philadelphia chromosome as determined by cytogenetic analysis and the bcr/abl translocation detected by PCR. Lymphoblastic crisis following mismatched, unrelated BMT is relatively rare. Moreover lymphoblastic malignancies usually respond less favorably to cell-mediated immunotherapy. This case is the first reported CML lymphoblastic crisis following mismatched unrelated BMT that responded to cell-mediated immunotherapy and IL-2. Some possible mechanisms and new therapeutic directions are discussed. Keywords: allogeneic unrelated BMT; CML blastic crisis relapse; donor leukocyte transfusion; interleukin-2 High-dose chemotherapy followed by allogeneic bone marrow transplantation (BMT) is currently the only curative treatment for chronic myelogenous leukemia (CML). 1 However, relapse post-BMT is still a major obstacle, occurring in 16% of patients following fully matched sibling BMT in first chronic phase.
agement of relapsed CML post-BMT is difficult since both cytostatic drugs and interferon-␣ do not usually provide a definite solution and a second BMT is associated with high treatment-related mortality. 4 Recently, leukocyte transfusions from the marrow donor have been shown to induce remission in CML patients who relapsed after HLA matched sibling BMT, and to lesser extent in other hematological malignancies, with the lowest success rate reported in acute lymphoblastic leukemia. 5 An inverse correlation has been observed between the tumor mass and the response to cell-mediated therapy, with a higher success rate in patients with minimal residual disease (molecular relapse) post-BMT. [6] [7] [8] [9] Some of the relapsing CML patients responded to donor leukocyte transfusions following in vivo and/or in vitro activation by interleukin-2, while no response was observed to unstimulated donor leukocyte infusions.
7,10 IL-2 may mediate both direct and indirect anti-tumor effects either via activation of immunocompetent cytotoxic cell populations or through secretion of cytokines, such as tumor necrosis factor-␣ (TNF␣) and interferon-␥. 9, 11 In contrast, data concerning donor leukocyte transfusions following unrelated and especially mismatched unrelated BMT are limited. 12, 13 We present a 21-year-old woman who underwent unrelated, one locus mismatched BMT while she was in CML chronic phase. Four months later she relapsed into lymphoid blastic crisis with new chromosomal translocations. She received a donor leukocyte transfusion from her mismatched, unrelated donor followed by in vivo IL-2. Full hematological, cytogenetic and molecular remission was achieved.
Case report
A 21-year-old woman was diagnosed as having Philadelphia-positive CML in chronic phase in February 1989. She was treated with busulfan for a year, then with native interferon-α and Ara-C for 3 years. Since she did not have an HLA-identical sibling donor, the search for an unrelated donor was initiated.
In May 1996, while still in first chronic phase, she was admitted for one locus mismatched (locus B), unrelated BMT from a sex-mismatched donor. She was conditioned Figure 1 At the time of lymphoblastic relapse cytogenetic analysis identified the Philadelphia chromosome t(9,22)(q34;q11) del(9)(p22), and two additional translocations t(2:3)(p22:q29), t(5;6)(q31;q13) (the arrows show chromosomal abnormalities).
for BMT with a protocol that included rabbit anti-thymocyte globulin 10 mg/kg/day for 4 days, i.v. cyclophosphamide 60 mg/kg/day for 2 days and total body irradiation of 1200 cGy in six fractions over 3 days. As graft-versus-host disease (GVHD) prophylaxis she received cylosporin A and a short course of methotrexate. She also received ganciclovir as prophylaxis for cytomegalovirus reactivation. Twenty-four hours following the last radiation fraction she received 6.0 × 10 8 nucleated cells/kg untreated bone marrow from the selected unrelated donor. The post-transplant course was uneventful. She engrafted on day +24 with WBC 1.1 × 10 9 /l, ANC 0.75 × 10 9 /l and platelets were 25 × 10 9 /l on day +18. There were no clinical signs of GVHD. At this time 100% donor cells were detected in bone marrow, using a Y chromosome probe. Neither the Philadelphia chromosome nor the bcr/abl translocation was detected by either cytogenetic or PCR techniques. The patient was discharged in good general condition. She was evaluated weekly in the outpatient clinic. Monthly cytogenetic and PCR evaluations showed 100% donor cells and no tumor marker was detected.
However, 4 months post-BMT her peripheral blood WBC count suddenly rose to 90.0 × 10 9 /l with 80% blasts and the platelet count dropped below 100.0 × 10 9 /l. Bone marrow aspiration revealed 98% lymphoblasts. Immunophenotyping confirmed the lymphatic origin of the blasts (CD7 77.5%). Cytogenetic analysis identified the Philadelphia chromosome t(9,22)(q34;q11) del(9)(p22), and two additional translocations t(2:3)(p22:q29), t(5;6)(q31;q13) ( Figure 1) .
It was felt that the only chance for this patient was to use adoptive cell-mediated immunotherapy from her bone marrow donor. An urgent appeal was therefore sent to the National Marrow Donor Program, which approved the peripheral blood lymphocyte donation (based on a protocol which was approved by the local Helsinki Committee).
The patient received 3.2 × 10 8 /kg unmanipulated peripheral blood leukocytes from her one locus mismatched unrelated donor followed by IL-2 injection s.c. (9 × 10 6 IU/day) for 3 consecutive days. Gradually, the blasts disappeared from the peripheral blood. On day +8 after cellmediated immunotherapy, erythroderma and maculopapular skin rash developed with moderate elevation of bilirubin, liver enzymes and diarrhoea. Clinical and pathological grade II GVHD (according to the IBMTR criteria) was diagnosed and 1 mg/kg/day i.v. solumedrol was given. A bone marrow aspirate taken on day +12 following cellmediated immunotherapy showed complete cytogenetic and molecular remission, donor origin hemopoiesis (Figure 2 ) with complete disappearance of the Philadelphia chromosome and other translocations. Similarly, no bcr/abl translocation could be detected by PCR. However, 3 weeks later the patient's condition deteriorated and she developed fever of 39°C, neurological manifestations, bleeding episodes and aggravation of GVHD of the skin and liver (grade IV). She was treated with broadspectrum antibiotics, amphotericin B, colloids as well as platelets and packed cell support. Repeated peripheral blood and bone marrow examinations including cytogenetic and molecular tests showed 100% donor cells and complete remission. However, her clinical condition continued to deteriorate and on day +26 she died from overwhelming sepsis.
Discussion
This case represents the first report of inducing a complete remission with no detectable blasts of CML in blastic crisis by mismatched unrelated donor leukocyte transfusion after single locus mismatched, T cell non-depleted BMT. This case may indicate not only that IL-2 activated immunocompetent cytotoxic T lymphocytes or NK cells from an allogeneic donor are able to react with residual leukemic cells in persistent minimal residual disease or documented molecular/cytogenetic relapse early after BMT, but also that they are able to reverse a full-blown blast crisis with new chromosomal translocations following allogeneic BMT. This case illustrates that allogeneic unrelated mismatched mononuclear cells have a striking capacity to identify, attack and destroy CML cells in blastic crisis, resulting in substantial response. Although both animal and clinical data indicate that GVL effects may occur independently of GVHD, in the majority of cases GVL is associated, at least to some extent, with GVHD. 6 The effectiveness of donor lymphocyte infusions can be enhanced by coadministration of IL-2, an activator of T and NK cells which has been shown to induce strong anti-tumor effects in animal models of hematological malignancies.
14 Our clinical observations indicate that allo-reactive donor T cells given in graded increments provide a powerful therapeutic tool for the elimination of residual CML cells that have escaped chemoradiotherapy. 7 A promising approach would be to insert suicide genes into donor T lymphocytes to ensure their finite life-span, while retaining their beneficial effects on engraftment and tumor control without severe GVHD. 15 The response of relapsed patients to donor lymphocyte infusions raises the possibility of using this method with non-myeloablative conditioning regimens, thereby avoiding the sometimes severe and fatal organ toxicities of the currently utilized preparative chemoradiotherapy combinations. 16 The ability to treat relapsed CML, with donor leukocyte transfusions in an unrelated, mismatched situation and avoid a second transplant is a significant development in BMT. However, as the GVL effect may be accompanied by lethal GVHD (20-30%), future research should be directed towards achieving the GVL effect without the severe morbidity and mortality associated with GVHD.
